Novartis Q4 Results
↓
↑
Content
Click below to navigate
through the document
Company overview
Financial review
Conclusions
Appendix
References
LeqvioⓇ adoption continues to expand across regions
Sales evolution
USD m, % cc
US
Ex-US
FY USD 355m
+217%
+190%
123
GROWTH
US: Steady growth, ahead of advanced lipid lowering market¹
Adoption
• 3,500 facilities have ordered Leqvio® (+13% vs. Q3)
~55% of business is from in-office buy & bill
Continued execution on growth enablers
• Depth is increasing in key accounts
•
Buy & bill is fastest growing acquisition channel
Improved HCP targeting driving increase in breadth and depth
Ex-US: Rollout continues
29 countries with public reimbursement
• 39 countries have private (commercial) coverage
LEQVIO®
(inclisiran)
•
54
42
17
69
25
Q4 2022
Q4 2023
-
HCP healthcare professional. 1. Includes PCSK9 mAbs and bempedoic acid.
□ NOVARTIS | Reimagining Medicine.
•
Solid early uptake in China self-pay market
Outcomes trials
.
On track for readout 2026+
Constant currencies (cc), core results are non-IFRS measures; explanation can be found on page 49 of Condensed Financial Report.
Novartis Q4 Results | January 31, 2024
14View entire presentation